LDC000067

Research use only, not for human use.

LDC000067 is a highly specific and selective CDK9 inhibitor with an IC50 value of 44±10 nM.

LDC000067 is a potent and selective CDK9 inhibitor. LDC000067 inhibited in vitro transcription in an ATP-competitive and dose-dependent manner. Gene expression profiling of cells treated with LDC000067 demonstrated a selective reduction of short-lived mRNAs, including important regulators of proliferation and apoptosis. Analysis of de novoRNA synthesis suggested a wide ranging positive role of CDK9. At the molecular and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells.

LDC000067; LDC-000067; LDC 000067

Others

Other Targets

CDK1; CDK2; CDK4; CDK6; CDK9

Cancer

——

1073485-20-7

370.43

C18H18N4O3S

98%

DMSO : ≥ 47 mg/mL 126.88 mM

COc1ccccc1c1cc(ncn1)Nc1cccc(c1)CS(=O)(=O)N

6-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)quinoline

(-20℃)

With Ice Pack

≥ 2 years